CDMRP Peer Reviewed Medical Research Program Clinical Trial Award | W81XWH 19 PRMRP CTA

Opportunity Information: Apply for W81XWH 19 PRMRP CTA

The CDMRP Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award is a Department of Defense funding opportunity aimed at moving clinical research quickly into real-world testing when there is a strong chance the results could meaningfully change care for patients. The program is specifically focused on clinical trials that address at least one of the Congressionally directed FY19 PRMRP Topic Areas, meaning applicants need to align their proposed trial with one or more of those designated disease or condition areas to be responsive. The intent is practical and impact-driven: support trials that can deliver clear evidence about whether an intervention works, how well it works, and in which patient populations it provides benefit.

This award supports a broad range of clinical trial designs, from early exploratory efforts through larger, more definitive studies. On the early end, it can include small proof-of-concept trials such as pilot studies, first-in-human studies, or Phase 0 trials, where the goal is often to demonstrate feasibility, gather initial safety or biological activity signals, refine procedures, and generate data that justify and shape subsequent, more advanced trials. On the later end, the program also allows for larger-scale trials intended to determine efficacy in relevant patient populations, which typically means evaluating clinical outcomes robustly enough to inform medical practice, guidelines, or further regulatory and implementation pathways.

The types of interventions that can be tested under this opportunity are intentionally wide-ranging. The announcement highlights trials evaluating promising new products, pharmacologic agents (including drugs or biologics), medical devices, clinical guidance, and emerging approaches or technologies. In practical terms, that scope could encompass testing a novel therapeutic, repurposing an existing drug for a new indication, evaluating a device-based intervention, validating a new clinical workflow or decision support approach, or assessing a technology-enabled method of delivering or monitoring care. What ties these together is the clinical trial requirement and the expectation that the work is positioned to create a significant impact on the targeted condition.

Administratively, this opportunity was released by the Department of Defense, Department of the Army, through the U.S. Army Medical Research Acquisition Activity (USAMRAA). The funding opportunity number is W81XWH 19 PRMRP CTA, and it falls under the Science and Technology and other Research and Development activity category, with CFDA number 12.420. The funding instruments listed are Cooperative Agreement and Grant, which signals that awards may be structured either as traditional grants or with a more collaborative federal role typical of cooperative agreements, depending on the needs and oversight requirements of the specific project. Eligibility is listed as unrestricted, meaning it is open to any type of entity, with the caveat that applicants must follow any additional eligibility clarifications that would appear in the full announcement text.

In terms of timing and scale, the opportunity was created on January 15, 2019, with an original closing date of July 2, 2019, and it anticipated making about 9 awards. The listed award ceiling is shown as 0, which typically indicates the public summary record does not specify a maximum dollar cap in that field, rather than implying no funds are available; the full solicitation would normally provide the actual budget limits, cost categories, and any constraints. Overall, the program is designed for teams that are ready to execute a clinical trial promptly and can justify why their study is positioned to produce actionable, high-value results for one of the FY19 PRMRP topic areas.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "CDMRP Peer Reviewed Medical Research Program Clinical Trial Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jan 15, 2019.
• Applicants must submit their applications by Jul 02, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 9 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 19 PRMRP CTA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: